First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination

Journal of Nuclear Medicine

Volumn 54, Issue 5, 2013, Pages 691-698

  Wan, Weixing ^a,b   Guo, Ning ^c,d,e   Pan, Donghui ^a   Yu, Chunjing ^b   Weng, Yuan ^b   Luo, Shineng ^a   Ding, Hong ^a   Xu, Yuping ^a   Wang, Lizhen ^a   Lang, Lixin ^c   Xie, Qingguo ^d   Yang, Min ^a   Chen, Xiaoyuan ^c  

^a BEIJING HOSPITAL   (China)

^b Wuxi No 4 People's Hospital   (China)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e XIAMEN UNIVERSITY   (China)

Author keywords

Alfatide; Aluminum fluoride; Lung cancer; PET; RGD peptide

Indexed keywords

ALFATIDE F 18; ALUMINUM; FLUORIDE; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ALFATIDE; ALUMINUM FLUORIDE; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; DIAGNOSTIC AGENT; FLUORINE; OLIGOPEPTIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG PURIFICATION; DRUG SYNTHESIS; DRUG UPTAKE; FREEZE DRYING; HUMAN; HUMAN TISSUE; ISOTOPE LABELING; LUNG CANCER; LUNG TUBERCULOSIS; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOCHEMISTRY; CHEMISTRY; DIMERIZATION; FEASIBILITY STUDY; KINETICS; LUNG TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; PET; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

ALFATIDE; ALUMINUM FLUORIDE; LUNG CANCER; PET; RGD PEPTIDE;

AGED; DIMERIZATION; FEASIBILITY STUDIES; FLUORINE RADIOISOTOPES; FREEZE DRYING; HUMANS; ISOTOPE LABELING; KINETICS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; OLIGOPEPTIDES; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY;

EID: 84877116526     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.113563     Document Type: Article

References (33)

1. Singh M, Ferrara N. Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol. 2012;30:648-657.
2. Kubota Y. Tumor angiogenesis and anti-angiogenic therapy. Keio J Med. 2012;61:47-56.
3. Chauhan VP, Stylianopoulos T, Martin JD, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol. 2012;7:383-388.
4. 3 Expression. Theranostics. 2011;1:48-57.
5. Haubner R,Wester HJ. Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr Pharm Des. 2004;10:1439-1455. (Pubitemid 38559759)
6. 3 integrin levels. Radiology. 2011;260:182-191.
7. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2:91-100. (Pubitemid 37328796)
8. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79:1157-1164.
9. Niu G, Chen X. Why integrin as a primary target for imaging and therapy. Theranostics. 2011;1:30-47.
10. Zhou Y, Chakraborty S, Liu S. Radiolabeled cyclic RGD peptides as radiotracers for imaging tumors and thrombosis by SPECT. Theranostics. 2011;1:58-82.
11. Morrison M, Cuthbertson A. Integrin imaging to evaluate treatment response. Theranostics. 2011;1:149-153.
12. 18F labeled knottin peptides. Theranostics. 2011;1:403-412.
13. Lang L, Li W, Jia HM, et al. New methods for labeling RGD peptides with Bromine-76. Theranostics. 2011;1:341-353.
14. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol. 2004;31:179-189.
15. 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol. 2004;6:350-359.
16. 68Ga-labeled c(RGDyK)- isothiocyanatobenzyl-1,4,7-triaza-cyclononane- 1,4,7-triacetic acid and feasibility studies in mice. J Nucl Med. 2008;49:830-836.
17. 3 expression. Eur J Nucl Med Mol Imaging. 2008;35:1100-1108.
18. 89Zr-RGD peptides. Mol Imaging Biol. 2011;13:1224-1233.
19. 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879-886.
20. Shi J, Zhou Y, Chakraborty S, et al. Evaluation of in-labeled cyclic RGD peptides: effects of peptide and linker multiplicity on their tumor uptake, excretion kinetics and metabolic stability. Theranostics. 2011;1:322-340.
21. 68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice. Bioconjug Chem. 2011;22:2415-2422.
22. 68Ga]Ga-NOTA-PRGD2 using a reference tissue model. PLoS ONE. 2012;7:e37506.
23. 18F-Labeled monomeric and dimeric RGD peptides using compartment model. Mol Imaging Biol. 2012;6:743-752.
24. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990;10:740-747.
25. Kimura Y, Naganawa M, Shidahara M, Ikoma Y, Watabe H. PET kinetic analysis-pitfalls and a solution for the Logan plot. Ann Nucl Med. 2007;21:1-8. (Pubitemid 46280143)
26. 64Cu-DOTA-RGD kinetics in tumor-bearing mice. J Nucl Med. 2009;50:250-258.
27. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996;16:834-840. (Pubitemid 26292051)
28. 18F-AlF-NOTA-RGD2 for tumor angiogenesis PET imaging. Eur J Nucl Med Mol Imaging. 2011;38:1732-1741.
29. 3 expression. Mini Rev Med Chem. 2006;6:227-234.
30. 5-integrin imaging agent. J Nucl Med. 2011;52:424-430.
31. 18F]FPP (RGD)2: an automated multi-step radiosynthesis for clinical PET studies. Mol Imaging Biol. 2012;14:88-95.
32. 3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6610-6616.
33. 99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study. J Nucl Med. 2012;53:716-722.